- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06400992
Investigation of Sky Automatic Technologies in Pediatrics (SKY-MARVEL)
Study Overview
Status
Conditions
Intervention / Treatment
- Device: Cochlear implant processor Sky CITM M90 (CI-5295)
- Device: Hearing Aid, including sound processor Phonak: Sky Link M90
- Diagnostic test: French simplified matrix test (FraSimat)
- Behavioral: Audiologist Fitting Questionnaire
- Behavioral: Patient Satisfaction Questionnaire
- Behavioral: AutoSens Feedback Discussion Form
Detailed Description
The ability to hear speech in noise is particularly important for children, as they are often in complex listening situations like classrooms or playgrounds. In children with hearing loss, the ability to understand speech in noise is further degraded not only by decreased audibility of speech sounds, but also additionally by the distortion spectral and temporal processing cues, and reduced binaural processing abilities. Cochlear implant manufacturers have introduced a number of technologies designed to improve speech recognition in background noise. Sound processing algorithms use a variety of strategies to facilitate listening in noise, and research has shown that these advances do lead to improved performance.
AutoSense Sky OS 3.0 (AutoSense Sky OS, AS) is an automatic auditory scene classification system specifically designed for children's typical listening situations, like classrooms and playgrounds. This technology is available in the new Sky CI M90 (Sky CI), which is the latest generation of sound processor (SP) from Advanced Bionics, designed for children.
This algorithm is also available in the Sky Link M90 hearing aid (Sky Link). This means that bimodal patients, using one Sky Link and one Sky CI can benefit from AutoSense Sky OS in addition to children with two Sky CI. The combination of the two hearing devices (HD) tested in this research, whether it be two Sky CI or one Sky CI and one Sky Link, will be referred to as the Sky Hearing System (Sky HS).
As usual in standard care, children with Sky HS can have their hearing system programmed in three ways (at the discretion of the clinician):
- Omnidirectional mode, in which the AutoSense Sky OS is deactivated and no modifications are made by the clinician (no sound treatment)
- AS Target, in which the AutoSense Sky OS is active and programmed with the parameters suggested by the programming software (Target) and no modifications are made by the clinician
- AS clinic, in which the AutoSense Sky OS is active, and settings have been modified by the clinician (mixed setting).
The goal of this research is to compare speech in noise perception in each of those three possible programming conditions used in the standard care. The hypothesis of this research is that the AS Target setting provides the best estimate of the settings required to optimize listening in noise. As such, it is expected that speech in noise performance will be best in the AS Target condition.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nathalie LOUNDON, MD, PhD
- Phone Number: +33 01 71 39 67 82
- Email: natalie.loundon@aphp.fr
Study Contact Backup
- Name: Gael PLASTOW
- Phone Number: +33 0144381711
- Email: gael.plastow@aphp.fr
Study Locations
-
-
-
Paris, France, 75015
- Recruiting
- Audiophonology Unit of the Ear, Nose and Throat (ENT) Department ("Oto-rhino-laryngologie (ORL) et chirurgie cervico-faciale") at the Necker-Enfants Malades hospital (AP-HP).
-
Principal Investigator:
- Nathalie LOUNDON, MD,PhD
-
Contact:
- Melissa MACSKILL
- Phone Number: +33 01 87 89 29 14
- Email: melissa.macaskill-ext@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be between 6 and 16 years of age at the time of inclusion
- Use spoken French as their primary mode of communication
- Ability to perform the Simplified French Matrix test in Noise
- Bimodal group: use the Sky CI processor or be eligible for a Sky CI processor upgrade on one side and use a contralateral hearing aid
- Bilaterally implanted group: use two Sky CI processors or be eligible for an upgrade to two Sky CI processors
- Obtain signed consent from legal guardian(s)
- Be enrolled in a health insurance plan or eligible for coverage
Exclusion Criteria:
- Severe neurological pathology identified prior to inclusion identified by MRI + /- neuro-pediatric workup
- Severe cognitive, psychiatric, or developmental disabilities identified prior to inclusion
- Family does not understand French
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Bilaterally implanted patients
patient with two cochlear implant in each ear
|
The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:
The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine. The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:
The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target.
The speech will be presented from the front, noise from 180°.
Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use.
The audiologist will go over the instructions for filling out the questionnaire at inclusion.
Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
|
|
Experimental: Bimodal patients
patient with cochlear implant in one ear and fitted with hearing aid audio in the other ear
|
The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine. The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:
The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target.
The speech will be presented from the front, noise from 180°.
Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use.
The audiologist will go over the instructions for filling out the questionnaire at inclusion.
Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Speech in noise perception (FraSimat)
Time Frame: 6 months
|
Difference in the FraSimat score obtained with the Sky HS programmed in Omni versus the score obtained in AS Target.
The scores vary from -15,0 to +15,0, the higher the score is, better is the patient's hearing comprehension.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Speech in noise perception (FraSimat)
Time Frame: 6 months
|
Difference in the FraSimat score obtained with the Sky HS programmed in AS Clinic versus the score obtained in Omni.
The scores vary from -15,0 to +15,0, the higher the score is, better is the patient's hearing comprehension.
|
6 months
|
|
Speech in noise perception (FraSimat)
Time Frame: 6 months
|
Difference in the FraSimat score obtained with the Sky HS programmed in AS Clinic versus the score obtained in AS Target.
The scores vary from -15,0 to +15,0, the higher the score is, better is the patient's hearing comprehension.
|
6 months
|
|
Patient satisfaction - device
Time Frame: 6 months
|
A patient questionnaire will be used to determine patient satisfaction with the devices.
The scores vary from 0 to 10, the higher the score is better is the patient's satisfaction.
|
6 months
|
|
Patient satisfaction -listening
Time Frame: 6 months
|
With the help of the audiologist, patients will discuss and rate listening quality in different listening situations.
The scores vary from 1 to 5, the higher the score is better is the patient's listening quality.
|
6 months
|
|
Audiologist programming modifications
Time Frame: 6 months
|
An audiologist questionnaire will be used to determine the programming modifications and decisions made by the audiologist for each individual patient.
The questionnaire doesn't involve any scoring.
|
6 months
|
Collaborators and Investigators
Investigators
- Study Director: Nathalie LOUNDON, MD,PhD, APHP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Otorhinolaryngologic Diseases
- Sensation Disorders
- Ear Diseases
- Hearing Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Hearing Loss
- Equipment and Supplies
- Electrical Equipment and Supplies
- Wearable Electronic Devices
- Sensory Aids
- Hearing Aids
Other Study ID Numbers
- APHP230143
- 2023-A02351-44 (Other Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss
-
MED-EL Elektromedizinische Geräte GesmbHCompletedHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Unilateral | Hearing Loss, MixedAustria, Germany, United Kingdom
-
Oticon MedicalCompletedEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Truway Health, Inc.Enrolling by invitationSensorineural Hearing Loss | Tinnitus | Sudden Hearing Loss | Acoustic Trauma | Inner Ear Injury | Noise-Induced Hearing Loss | Vestibular DysfunctionUnited States
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteRecruitingHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Noise-Induced | Hearing Loss, Unilateral | Hearing Loss, Mixed | Hearing Disorders in ChildrenUnited States
-
Envoy Medical CorporationActive, not recruitingSensorineural Hearing Loss | Sensorineural Hearing Loss (Disorder) | Sensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound | Sensori-Neural DeafnessUnited States
-
Oticon MedicalCompletedConductive Hearing Loss | Conductive and Sensori-neural Hearing Loss in the Same Ear | Unilateral, Profound Sensori-neural Hearing LossUnited States
-
Wonju Severance Christian HospitalRecruitingHearing Loss, Sudden | Sudden Hearing Loss | Hearing Loss, Idiopathic Sudden Sensorineural | SSNHL(Sudden Sensory Neural Hearing Loss)Korea, Republic of
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
Clinical Trials on Cochlear implant processor Sky CITM M90 (CI-5295)
-
Advanced Bionics AGCompletedCochlear Hearing LossGermany
-
Advanced BionicsCompletedOtorhinolaryngologic Diseases | Ear Diseases | Hearing Loss | Hearing DisordersUnited States